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Received October 31, 2012; accepted April 9, 2013AbstractBackground: Insulin-like growth factor (IGF)-I is primarily produced by the liver under the stimulation of growth hormone, and has systemic
growth effects. Placental growth hormone in maternal circulation increases from early pregnancy and is responsible for the increment in maternal
serum IGF-I. The purpose of this study was to evaluate the changes in maternal serum IGF-I during pregnancy and their relationship to maternal
anthropometry, including body weight (BW) and body mass index (BMI).
Methods: We obtained 332 blood samples from 114 expectant mothers at different gestational ages (Gas) without adverse medical history. Serum
IGF-I levels were measured by immunoradiometric assay. Linear regression analysis for continuous variables and t test for comparisons of
categorical variables were used to test for significance.
Results: Maternal serum IGF-I during pregnancy was significantly correlated not only to GA ( p < 0.001, r ¼ 0.358), but also to maternal BW
( p ¼ 0.001, r ¼ 0.202), and maternal BMI ( p < 0.001, r ¼ 0.263). The mean maternal IGF-I was highest in the third trimester [1st vs. 2nd,
p < 0.001, 95% confidence interval (CI) ¼ 70.17 to 28.22; 1st vs. 3rd, p < 0.001, 95% CI ¼ 138.02 to 76.94; 1st vs. 3rd, p < 0.001, 95%
CI ¼ 88.86 to 27.71].
Conclusion: Maternal serum IGF-I is significantly related to GA, maternal BW, and BMI during pregnancy.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Insulin-like growth factor (IGF)-I, also known as somato-
medin C, is primarily produced by the liver as an endocrine
hormone. However, it also functions in a paracrine/autocrine
fashion in selected target tissues. Its production can be stim-
ulated by growth hormone (GH) and decreased by malnutri-
tion, growth hormone insensitivity, and lack of GH receptors.
The molecular structure of IGF-I is similar to that of insulin,
and its primary action is mediated by binding to its specific
receptor, IGF-I receptor, which is present on many tissues.
Binding to its receptor, IGF-I stimulates systemic body growth* Corresponding author. Dr. Ming-Jie Yang, Department of Obstetrics and
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http://dx.doi.org/10.1016/j.jcma.2013.07.004and has growth-promoting effects on almost every cell in the
body, especially skeletal muscle, bone, cartilage, liver, kidney,
nerves, skin, hematopoietic cells, and lungs, as well as cellular
DNA synthesis. Consequently, deficiency of either GH or IGF-
I results in diminished stature.
Hypertrophy of the mammary glands during pregnancy
results in increased concentration of IGF-I; hence, a relation-
ship between the development of the mammary glands and
IGF-I can be found.1 Moreover, IGF-I can also be found in the
intervillous space during pregnancy.2 The placental syncytio-
trophoblast produces a variant of pituitary GH (variant GH or
placental GH)3 that gradually replaces pituitary GH in
maternal circulation, which starts at 8 weeks of gestation and
becomes elevated during pregnancy.4 Placental GH is thought
to be responsible for the increase in maternal serum levels of
IGF-I.5 Fetal growth during pregnancy may be mediated by
placental GH via regulation of IGF-I.6 Previous studies havehinese Medical Association. All rights reserved.
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the combined changes of fetal size, maternal weight, and
placental mass during pregnancy.7e9 Theoretically based on
the above findings, changes in maternal IGF-I during preg-
nancy should be evident. However, the relationships among
maternal IGF-I and gestational age (GA), as well as changes in
maternal anthropometry have rarely been reported, and this
was the purpose of our present study.
2. Methods2.1. SamplesBlood samples were collected after obtaining written con-
sent from singleton women without an adverse medical history
during their first prenatal visit, Down’s screen test, 50-g
glucose challenge test, hepatitis B markers test, and admis-
sion for delivery. Samples were drawn during the daytime
when possible to avoid the effect of time bias, spun at 4000 g
for 10 minutes, and stored at 20 C until assay. The study
project was approved by the Institutional Review Board of
Taipei Veterans General Hospital (IRB No. 2011-12-017IB#1).
The expected date of delivery was calculated based on the
first day of the last menstrual period when pregnancy was
detected immediately after a missed period. When no reliable
menstrual dates were available or menstrual cycles were
irregular, ultrasound was used to date the pregnancy. Maternal
characteristics including body height, body weight (BW), and
GA of each blood test, as well as the time of delivery were all
recorded. Body mass index (BMI) was calculated using the
formula weight/height.22.2. IGF-I assayTable 1
Demographic data of patients.
Average (range)
No. 114
Age, y 29.9  4.0 (19e40)
Gravidity 2.3  1.2 (1e7)
Parity 0.7  0.7 (0e3)
Blood tests, samples 2.8  1.3 (1e5)
Maternal body height, cm 159.8  5.0 (147e170)
Preconceptional body weight, kg 52.3  7.1 (39.5e81.3)
Preconceptional body mass index, kg/m2 20.5  2.7 (15.4e34.3)
Body weight at delivery, kg 67.1  7.9 (49.0e92.0)
Body mass index at delivery, kg/m2 26.3  3.0 (19.5e37.9)The serum concentrations of IGF-I were measured with
ACTIVE non-extraction IGF-I IRMA (immunoradiometric
assay; Diagnostic Systems Laboratories, Webster, TX, USA) by
the Department of NuclearMedicine. The procedure used a two-
site IRMAprinciple described byMiles et al,10 andwas designed
to detect IGF-I. The IRMAwas a noncompetitive assay in which
the analyte (recombinant human IGF-I) to be measured was
sandwiched between two antibodies. The first antibody was
immobilized to the inside walls of the tubes and the other anti-
body was radiolabeled (iodine-125-labeled anti-IGF-I) for
detection. The analytes present in the unknowns, standards, and
controls were bound by both antibodies to form a sandwich
complex. Unbound reagents were removed by decanting and
washing the tubes. The minimal detectable concentration of
IGF-I was 2.06 ng/mL. The intra- and interassay coefficients of
variations (CVs) were 4.8% and 5.1%, respectively.Gestational age at delivery, wk 38.8  1.3 (37e42)
Delivery methods2.3. Statistical analysis
NSD 82
C/S 32
Newborn sex
Male 55
Female 59
C/S ¼ cesarean section; NSD ¼ normal spontaneous delivery.Statistical analysis for linear regression between continuous
variables, and t test for comparison of categorical variables
were done with SPSS software for Windows, version 20 (IBM
SPSS Inc. Chicago, IL, USA), with p < 0.05 as significant.3. Results
There were 332 blood samples obtained from 114 expectant
mothers in this study. The average age of the participants was
29.9  4.0 years with a range of 19e40 years. The range of
gravidity was 1e7 with a mean of 2.3  1.2. Mean parity was
0.7  0.7 with a range of 0e3. The average maternal height
was 159.8  5.0 cm and ranged between 147 cm and 170 cm.
The mean preconceptional BW was 52.3  7.1 kg and the
range was 39.5e81.3 kg. The preconceptional BMI was
15.4e34.3 kg/m2 with a mean of 20.5  2.7 kg/m2. The mean
maternal BW at delivery was 67.1  7.9 kg with a range of
49.0e92.0 kg. The range of maternal BMI at delivery was
19.5e37.9 kg/m2 with an average of 26.3  3.0 kg/m2. The
gestational age at delivery ranged between 37 weeks and 42
weeks with a mean of 38.8  1.3 weeks. There were 82 natural
spontaneous deliveries and 32 cesarean sections. There were
55 male and 59 female newborns. The mean number of blood
samples offered by the expectant mothers was 2.8  1.3,
ranging from 1 sample to 5 samples (Table 1).
Throughout the whole course of pregnancy, maternal serum
levels of IGF-I ranged from 10.0 ng/mL to 735.4 ng/mL. IGF-I
was significantly correlated to GA ( p < 0.001, r ¼ 0.358;
Fig. 1), maternal BW ( p ¼ 0.001, r ¼ 0.202; Fig. 2), and
maternal BMI ( p < 0.001, r ¼ 0.263; Fig. 3). Both maternal
BW and BMI were related to GA (BW vs. GA, p < 0.001,
r ¼ 0.603; BMI vs. GA, p < 0.001, r ¼ 0.600). Seemingly,
maternal BW is significantly correlated to BMI ( p < 0.001,
r ¼ 0.905; Table 2).
In the first trimester (GA < 13 weeks), 37 blood samples
were collected and serum levels of IGF-I ranged from 14.2 ng/
mL to 215.1 ng/mL, with an average of 93.8  44.2 ng/mL.
There was no significant correlation between maternal serum
levels of IGF-I with early GA ( p ¼ 0.241, r ¼ 0.221),
maternal BW ( p ¼ 0.597, r ¼ 0.101), and maternal BMI
( p ¼ 0.717, r ¼ 0.069). Nevertheless, maternal BW was
correlated with BMI ( p < 0.001, r ¼ 0.809), but neither was
Fig. 1. Relationship between maternal serum insulin-like growth factor-I and
gestational age (GA) throughout the whole pregnancy.
Fig. 3. Relationship between maternal serum insulin-like growth factor-I and
maternal body mass index (BMI) throughout the whole pregnancy.
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r ¼ 0.224; BMI vs. GA, p ¼ 0.735, r ¼ 0.064; Table 2).
One hundred and ninety-one samples were obtained during
the second trimester (defined by GA >12 weeks and <29
weeks). Maternal serum levels of IGF-I ranged between
10.0 ng/mL and 548.9 ng/mL. The mean value was
145.7  104.6 ng/mL. A significant correlation was found
between maternal serum levels of IGF-I and GA, with
p ¼ 0.001 (r ¼ 0.272; Fig. 4). Although, IGF-I was not
correlated with maternal BW ( p ¼ 0.123, r ¼ 0.126), it was
significantly related to maternal BMI ( p ¼ 0.018, r ¼ 0.192;
Fig. 5). At the same time, maternal BW was not only corre-
lated with BMI ( p < 0.001, r ¼ 0.860), but also related to GA
( p < 0.001, r ¼ 0.428). Maternal BMI was significantly
correlated with GA as well ( p < 0.001, r ¼ 0.474; Table 2).
There were 104 blood samples obtained in the third
trimester. The IGF-I levels ranged between 11.2 ng/mL andFig. 2. Relationship between maternal serum insulin-like growth factor-I and
maternal body weight (BW) throughout the whole pregnancy.735.4 ng/mL with a mean of 202.5  140.8 ng/mL. Serum
IGF-I was not related to GA ( p ¼ 0.818, r ¼ 0.026), maternal
BW ( p ¼ 0.612, r ¼ 0.058), or maternal BMI ( p ¼ 0.662,
r ¼ 0.050), although maternal BW was significantly related to
both BMI ( p < 0.001, r ¼ 0.838) and GA ( p ¼ 0.017,
r ¼ 0.267). Significant correlation was also found between
maternal BMI and GA ( p ¼ 0.023, r ¼ 0.256; Table 2).
Comparison of maternal serum IGF-I among the three tri-
mesters revealed the highest level of significance in the third
trimester (1st vs. 2nd, p < 0.001, 95% confidence interval
(CI) ¼ 70.17 to 28.22; 1st vs. 3rd, p < 0.001, 95%
CI ¼ 138.02 to 76.94; 2nd vs. 3rd, p < 0.001, 95%
CI ¼ 88.86 to 27.71; Table 3).
4. Discussion
Previous reports have discussed the relationship between
neonatal outcomes, such as preterm birth, intrauterine growth
restriction, or pregnancy-induced hypertension, and maternal
serum IGF-I, IGF binding proteins (IGFBPs), IGF-I binding
protein receptors.11,12 However, the changes in levels of
maternal serum IGF-I during pregnancy have seldom been
mentioned. Holmes et al11 reported a significant increase in
maternal IGF-I and IGFBP-3 with advancing GA, and in cases
of fetal growth restriction, maternal IGF-I was significantly
lower ( p ¼ 0.001). Compared with that study, our sample size
was larger and yielded more convincing results. Similar results
were found by Wang et al9 showing the highest significant
maternal serum IGF-I during the third trimester. Nevertheless,
the linear correlations between IGF-I and GA as well as
maternal anthropometry were not shown.
Klauwer et al12 presented the relationship between
maternal serum levels of total IGF-I, free IGF-I, IGFBPs, and
fetal or newborn growth in 1997. Free IGF-I has a direct effect
on target tissues or cells. The methodology in this study used a
two-site immunoradiometric assay to detect IGF-I in serum
Table 2
Inter-relationships of maternal serum IGF-1, BMI, BW, and GA during the three trimesters and throughout the whole pregnancy.
First trimester Second trimester Third trimester Whole pregnancy
p r p r p r p r
IGF-1 vs. GA 0.241 0.221 0.001 0.272 0.818 0.026 <0.001 0.358
IGF-1 vs. BW 0.597 0.101 0.123 0.126 0.612 0.058 0.001 0.202
IGF-1 vs. BMI 0.717 0.069 0.018 0.192 0.662 0.050 <0.001 0.263
BW vs. GA 0.235 0.224 <0.001 0.428 0.017 0.267 <0.001 0.603
BMI vs. GA 0.735 0.064 <0.001 0.474 0.023 0.256 <0.001 0.600
BMI vs. BW <0.001 0.809 <0.001 0.860 <0.001 0.838 <0.001 0.905
The values were compared by linear regression analysis.
BMI ¼ body mass index; BW ¼ body weight; GA ¼ gestational age; IGF ¼ insulin-like growth factor.
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therefore, additional detection of IGFBPs or total IGF-I was
unnecessary.
Although a significant correlation between GA and
maternal serum levels of IGF-I was found throughout preg-
nancy, there was no significant correlation between them in the
first trimester. During this period, patients usually have sleep
disturbance, dizziness, breast engorgement, headache, and
gastrointestinal discomfort such as nausea, vomiting, and
changes in appetite.13 Consequently, major BW change in
pregnant women during the first trimester is not commonly
seen. The embryonic size and chorion frondosum do not have
apparent increments in the first trimester, and maternal total
body mass does not usually increase. As a result, maternal
serum levels of IGF-I do not correlate with GA or maternal
BW in the first trimester.
Normally the greatest change in maternal BW is seen
during the second trimester, resulting from improved appe-
tite. It has been observed that there is an apparent increase
in body mass and blood volume, hyperplasia of adipose
tissue and mammary glands,1 reinforcement of the skel-
etomuscular system,14 and positive effects on other or-
gans.15 During this stage of pregnancy, there is additional
fetal weight and placental mass increase with advancingFig. 4. Relationship between maternal serum insulin-like growth factor-I and
gestational age during the second trimester.GA. It has been noted that IGF-I is involved in these
changes. Data from our present study support the significant
correlation of maternal serum IGF-I with GA, maternal BW,
as well as BMI in the second trimester of pregnancy. This
finding is similar to the study performed by Clapp et al16 in
2004 in which a robust relationship was noted between the
increase in placental mass, neonatal fat mass, and maternal
IGF-I levels after 16 weeks. A similar result was also found
by Chellakooty et al17 in their longitudinal study of intra-
uterine growth and placental growth hormone-insulin-like
growth factor 1 axis in maternal circulation. They dis-
closed a highly significant association between the increase
in placental growth hormone and the increase in IGF-I along
with advancing GA.17
In the third trimester, although maternal BW and BMI
correlated with GA, there was no significant relationship be-
tween maternal IGF-I and GA. At the same time, maternal BW
and BMI were not correlated with maternal serum IGF-I. It is
difficult to explain the relationship among these factors (IGF-I,
maternal BW, BMI, and GA) in this period of gestation. This
phenomenon may be caused by the catabolic effect of
maternal adipose tissue and is probably due to the dilutional
effect from expanded maternal plasma volume in the third
trimester. However, further studies are needed to confirm this.Fig. 5. Relationship between maternal serum insulin-like growth factor-I and
maternal body mass index (BMI) during the second trimester.
Table 3
Comparisons of maternal IGF-I among the three trimesters with t test.
Trimester p 95% CI
1st vs. 2nd <0.001 70.2, 28.22
1st vs. 3rd <0.001 138.02, 76.94
2nd vs. 3rd <0.001 88.86, 27.71
CI ¼ confidence interval; IGF ¼ insulin-like growth factor.
639M.-J. Yang et al. / Journal of the Chinese Medical Association 76 (2013) 635e639In conclusion, our study was able to identify the relation-
ship between maternal IGF-I and GA through the entire
course of pregnancy, showing the highest level of significance
in the third trimester. It should also be noted that maternal
IGF-I was significantly related to BW and BMI throughout
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